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Education and debate
Role of external evidence in monitoring clinical trials:
experience from a perinatal trial
Peter Brocklehurst, Diana Elbourne, Zarko Alfirevic
The randomised controlled trial is the most scientifi›
cally rigorous way of evaluating interventions whose
effects on important clinical outcomes are uncertain.1
Before conducting such a trial, investigators should
undertake a systematic review of the evidence from
existing trials, including, if appropriate, a meta›analysis.
This prevents trials being carried out unnecessarily
when the answer to the clinical question is already
known. A priori power calculations should be made to
determine how many participants will be required to
answer the research question,2 and this process is
increasingly being required by research ethics commit›
tees and funding bodies, among others.3 Nevertheless,
under some circumstances recruitment to a trial may
be halted before the planned sample size has been
reached because
x Funding has run out or further recruitment has
become impossible because of a lack of interest in the
participating centres—“trial fatigue”
x The internal evidence emerging from accumulating
trial data suggests that continuing would be unethical4
x External evidence indicates that the trial should be
halted.5
The process for stopping a trial early because of
indications from internal data is well accepted and rec›
ognised and the statistical methodology has been
discussed at length, but this is not the case for external
evidence. The process by which trial investigators
should consider external evidence and make decisions
concerning further recruitment is unclear.
Methods
We describe our recent experience of stopping a large
international trial because of external evidence that
emerged after the trial had begun. Our aim is to illus›
trate some of the problems we encountered. On the
basis of this experience and relevant published reports,
we make practical suggestions for making this element
of data monitoring more explicit in future trials.
The trial
The antenatal thyrotropin releasing hormone trial was
set up to evaluate the use of thyrotropin releasing hor›
mone combined with corticosteroids in women at risk
of preterm labour.6 When the study was being planned,
six randomised controlled trials of thyrotropin
releasing hormone had already been performed and
had been combined in a systematic review and
meta›analysis.7 This review suggested that thyrotropin
releasing hormone might reduce the incidence of res›
piratory distress syndrome (overall relative risk 0.77;
95% confidence interval 0.61 to 0.98) in babies born to
mothers who had been treated with thyrotropin releas›
ing hormone. However, there were three problems
associated with the trial evidence. Firstly, many of the
studies only reported outcomes in a subset of babies
born within 10 days of their mothers’ recruitment to
the trial. Secondly, respiratory distress syndrome is a
surrogate measure of neonatal morbidity. Thirdly, the
trials were too small to be able to evaluate the effect of
thyrotropin releasing hormone on more substantive
outcome measures such as neonatal mortality or
chronic lung disease. The only trial of a reasonable size
was the Australian collaborative trial of antenatal
thyrotropin releasing hormone.8 However, this study
used a lower dose of thyrotropin releasing hormone
than the previous ones and showed no benefit for
babies whose mothers had received active treatment.
Definitive answer
The antenatal thyrotropin releasing hormone trial was
designed to provide a definitive answer to whether the
treatment was beneficial. It sought to recruit approxi›
mately 3800 women to evaluate the effect of thyro›
tropin releasing hormone compared with placebo on
Involvement in the
antenatal
thyrotropin
releasing hormone
trial is outlined on
the BMJ’s website
Summary points
Principal investigators of clinical trials should be
responsible for obtaining relevant information
emerging from other studies
Investigators should seek unpublished
confidential information, but this requires
sensitive handling
Meta›analysis is useful for incorporating ongoing
trial data with existing and emerging evidence
The trial data monitoring committee is
responsible for reviewing both internal and
external information, but the trial steering
committee should decide whether to modify or
stop a trial
Perinatal Trials
Service, National
Perinatal
Epidemiology Unit,
Institute of Health
Sciences, Oxford
OX3 7LF
Peter Brocklehurst
consultant clinical
epidemiologist
Medical Statistics
Unit, Department of
Epidemiology and
Population Health,
London School of
Hygiene and
Tropical Medicine,
London
WC1E 7HT
Diana Elbourne
reader in health care
evaluation
Department of
Obstetrics and
Gynaecology,
Liverpool Women’s
Hospital, Liverpool
L8 7SS
Zarko Alfirevic
senior lecturer
Correspondence to:
P Brocklehurst
peter.brocklehurst@
perinat.ox.ac.uk
BMJ 2000;320:995–8
995BMJ VOLUME 320 8 APRIL 2000 bmj.com
death and chronic lung disease. Approximately 200
centres in at least 10 different countries were expected
to recruit patients. The European Union’s biomed pro›
gramme and the UK Medical Research Council
supported the trial. In 1994›5, during the planning
stage, the trial investigators knew of two other ongoing
randomised controlled trials that were using the same
intervention in the same group of women. However,
these trials were smaller and had chosen respiratory
distress syndrome as their primary outcome. Contact
was made with the trial investigators of both trials in
order to monitor their progress.
The start of the antenatal thyrotropin releasing
hormone trial was delayed until the middle of 1996
because of prolonged negotiations with the pharma›
ceutical company which was donating the thyrotropin
releasing hormone and placebo. By early 1997,
however, 23 centres were recruiting subjects, 55 centres
had research ethics committee approval and were wait›
ing to start recruitment, and a further 69 centres were
applying for this approval. The centres were from 10
countries and 225 women had been randomised.
New external evidence
In the first half of 1997, new external information came
from three sources. Early in the year, confidential
information about the one year follow up of the
Australian trial became available to one of the
principal investigators of the antenatal thyrotropin
releasing hormone trial as part of a journal’s peer
review process. The data indicated that babies exposed
to thyrotropin releasing hormone in utero had lower
developmental scores at one year than the placebo
group. The steering committee of the Australian trial
made this information available to all the principal
investigators of the antenatal thyrotropin releasing
hormone trial. When the Australian data were eventu›
ally published, the principal investigators of the
antenatal thyrotropin releasing hormone trial called
an international telephone conference with the
Australian study’s steering committee.9 Because the
follow up data from the Australian trial were consistent
with its short term results and the steering committee
of the Australian study urged the antenatal thyrotropin
releasing hormone trial investigators to continue, it
was agreed to continue recruitment but to draw the
Australian trial data to the attention of collaborating
centres.
In May, the results of the two other trials were pre›
sented orally at a conference in Washington. Neither
trial detected any benefit of thyrotropin releasing hor›
mone on respiratory distress syndrome in neonates.
Reviewing the evidence
Because of these results, the principal investigators
suspended the antenatal thyrotropin releasing hor›
mone trial until its data monitoring and trial steering
committees could meet. In preparation for these meet›
ings, the data from the new trials were added to the
existing meta›analysis in which data from all trials that
had reported their intention to treat analysis were
combined (figure). This information, together with the
analysis of the first 225 women recruited to the
antenatal thyrotropin releasing hormone trial, was
given to the data monitoring committee, which had
been urgently convened in May 1997.
The committee’s terms of reference had been
included in the original trial protocol. The statistical
criteria for changing the protocol or stopping early
were based on the Peto rule.10 The data monitoring
committee recommended that the trial protocol be
amended to allow the trial to continue in a subgroup of
women who deliver within 10 days of receiving thyro›
tropin releasing hormone or placebo, if such a group
could be identified reliably at randomisation. (This
identification was not possible.)
Steering committee deliberations
The international steering committee met a few days
later to discuss the report of the data monitoring com›
mittee, the implications of the two, as yet unpublished,
trials of thyrotropin releasing hormone, and the follow
up of the Australian trial. The first part of the meeting
was spent discussing the process by which the new data
would be viewed. It was agreed that a meta›analysis of
the trials that included an intention to treat analysis
would be considered. The trial steering committee
agreed to consider stopping the trial if the new
meta›analysis showed that the incidences of death and
chronic lung disease were significantly greater in the
group receiving thyrotropin releasing hormone than
the placebo group or if there was evidence that any
potential benefit in the thyrotropin releasing hormone
group was too small to be considered clinically useful.
The committee agreed that it would be unnecessary to
continue the trial to show conclusively that thyrotropin
releasing hormone was harmful because the treatment
was not used widely.
The updated meta›analysis suggested that if thyro›
tropin releasing hormone was of any benefit, the rela›
tive reduction in the incidence of death or chronic lung
disease was unlikely to be more than 5%. The trial size
of 3800 had been based on detecting a relative
difference of 30%, as this was felt to be an important
difference that would change clinical practice. More
than 100 000 women would have to be recruited, how›
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ever, if the trial had to show a 5% relative difference
(assuming the incidence of the primary outcome was
10%, as was assumed in the initial sample size
estimate). After lengthy discussion, the trial steering
committee decided that there was no justification for
continuing the trial and recruitment was stopped.
Winding down process
A letter explaining why the trial had finished earlier
than expected was sent to all the recruiting centres and
the women who had so far been recruited. The staff
financed by the grant had their contracts shortened.
The women and babies recruited were followed up as
specified in the protocol, and the results were prepared
and analysed as planned.
Discussion
This example raises general questions about formalis›
ing the role of external evidence in the monitoring of
trials—how should this information be collected, who
should collect it, and how should external evidence be
incorporated into a steering committee’s decision
making process? We focus here on the practicalities of
this process, which could be applied within the statisti›
cal framework of “classical” or “bayesian” stopping
rules.11 In the antenatal thyrotropin releasing hormone
trial, three main groups were involved in this process—
the principal investigators, the trial steering committee,
and the data monitoring committee.
Role of the principal investigators
The principal investigators were the most closely
involved with the trial and the subject area. By staying
in close contact with investigators in related trials and
by working cooperatively they learned about new
external information before it was published. However,
because some of this information was given to them in
confidence, it could not be disseminated until it had
been published in a scientific journal. Even after infor›
mation had been presented at a scientific meeting,
widespread written dissemination was not allowed in
case this prejudiced subsequent journal publication.
With one exception (see below), the principal
investigators were not aware of the interim results of
the antenatal thyrotropin releasing hormone trial.
Role of the steering committee
In contrast to the principal investigators, the steering
committee in this trial was international and large
(although this situation may be uncommon). This
allowed the expression of a considerable breadth of
views but meant that it was not feasible to meet often.
In addition, the trial steering committee included inde›
pendent members who could not be expected to
devote large amounts of time to ascertaining external
evidence. Rather, the role of the trial steering
committee was to receive and interpret evidence
before making decisions. This role has been formalised
in the revised terms of reference for the trial steering
committee of a trial funded by the MRC. These include
the statement: “To review at regular intervals relevant
information from other sources, and to consider the
recommendations of the Data Monitoring and Ethics
Committee.”3
Role of the data monitoring committee
In general, the involvement of the data monitoring
committee is intermittent and its principal responsibil›
ity is to consider the accumulating data from within the
trial. In the case of the antenatal thyrotropin releasing
hormone trial, one of the principal investigators (PB),
working with the trial statistician, provided the data
monitoring committee with these data in confidence.
This principal investigator was not involved with the
recruitment of women to the trial.12 Details of the
external information were also provided in the report
to the data monitoring committee. In this case, there
were so few data from the antenatal thyrotropin releas›
ing hormone trial that almost the same information
was available to the data monitoring committee, the
principal investigators, and the trial steering com›
mittee. Usually, however, only the data monitoring
committee and those who service it will have this com›
prehensive overview.
Suggestions
On the basis of this experience, we suggest the follow›
ing division of responsibilities for including external
information into the trial monitoring process. The
principal investigators, a small group of people who
are closely involved in the trial and the subject area,
should be responsible for ascertaining any external
information in as timely a fashion as possible. This
process will be helped by regular updating of the
Cochrane database of reviews (at least where a review
is in existence), although personal contacts may speed
up this process even more. The role of information
provided confidentially (whether by the principal
investigators of related trials, the peer review process
by scientific journals, or other sources) presents an
additional level of complexity, requiring sensitive
discussions between the relevant parties.
A mechanism needs to be established for providing
the chair of the data monitoring committee with any
additional external information as it is ascertained. The
decision to call a formal meeting of the data monitor›
ing committee to consider additional information
should rest with the chairperson of the data
monitoring committee. In a rapidly moving area of
research, a formal meta›analysis is likely to be the most
appropriate way of presenting these data. The data
monitoring committee is an independent group and
the only body with full oversight of both the internal
and external evidence. It is in the best position to make
informed recommendations about whether it is ethical
for a trial to continue recruiting subjects or whether
the protocol should be amended. In making recom›
mendations based on all available evidence, the data
monitoring committee can use statistical rules that are
similar to those used in considering evidence from a
single trial. Having received such a recommendation, it
is the responsibility of the trial steering committee to
make the final decision about the future of the trial.
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Developing learning organisations in the new NHS
Huw T O Davies, Sandra M Nutley
The government’s quality strategy represents a bold
blueprint for the new NHS. It embodies the view that
managing the organisational culture in tandem with
improved learning (albeit overseen by close external
monitoring) will deliver substantial gains in perform›
ance. The avowed aim is “to create a culture in the NHS
which celebrates and encourages success and innova›
tion . . . a culture which recognises . . . scope for
acknowledging and learning from past mistakes.”1
Although learning is something undertaken and
developed by individuals, organisational arrangements
can foster or inhibit the process. The organisational
culture within which individuals work shapes their
engagement with the learning process. More than this,
there are serious questions about whether and how the
organisation can harness the learning achieved by its
individual members. Thus, although continuing
professional development has long been a part of the
NHS, evidence from other sectors suggests that learn›
ing needs to take a more central role. Organisations
that position learning as a core characteristic have
been termed “learning organisations,”2–4 and this
concept is an important one in the context of
organisational development.5
This paper explores organisational learning and
the characteristics of the organisational cultures
needed to underpin this learning. We have drawn on
existing publications in this area and have used
informal synthesis to summarise the key elements of
learning organisations and relate these to recent devel›
opments in the NHS. Our aim is to encourage the
transference of some of these ideas to the NHS.
Learning organisations
Individuals learn and enhance their personal capabili›
ties within organisations, but what does it mean to talk
of an organisation learning? Can a hospital, a general
practice, or a health authority be said to learn? An
organisation is not simply a collection of individuals;
the whole amounts to something greater than the sum
of the parts. Similarly, the learning achieved by an
organisation is not simply the sum of the learning
achieved by individuals within that organisation.
Individuals may come and go, but the organisation
(even in the turbulent world of health care) usually
endures. Robust organisations can still accumulate
competence and capacity despite the turnover of staff;
individual learning can be retained and deployed in
the organisation. How well any organisation can do
this depends on factors such as internal communica›
tion and the assimilation of individual knowledge into
new work structures, routines, and norms. Learning
organisations see a central role for enhancing personal
capabilities and then mobilising these within the
organisation.
Summary points
The national quality strategy for the new NHS
highlights lifelong learning as a way of improving
health care
Learning is something achieved by individuals,
but “learning organisations” can configure
themselves to maximise, mobilise, and retain this
learning potential
Learning occurs at different levels—single loop
learning is about incremental improvements to
existing practice; double loop learning occurs
when organisations rethink basic goals, norms,
and paradigms; and meta›learning reflects an
organisation’s attempts to learn about (and
improve) its ability to learn
Learning organisations attempt to maximise
learning capacity by developing skills in double
loop learning and meta›learning
Learning organisations exhibit several common
characteristics and are underpinned by distinctive
organisational cultures which the NHS may need
to adopt if it is to achieve substantial quality
improvements
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